scientific advisory board
Ulrich Von Andrian, MD, PhD

Mallinckrodt Professor of Immunopathology at Harvard Medical School.

For more information: http://vonandrian.hms.harvard.edu/About%202014.html

Ulrich H. von Andrian, M.D. received his M.D. from Ludwig-Maximilians University in Munich, Germany. He did postdoctoral work at the La Jolla Institute for Experimental Medicine and, subsequently, at Stanford University in California. He then went on to Harvard in 1994 as an Assistant Professor of Pathology at HMS, and was Senior Investigator at the CBR Institute for Biomedical Research (now called The Immune Disease Institute or IDI). He is currently the Edward Mallinckrodt Jr. Professor of Immunopathology at Harvard Medical School. Uli is a member of the European Academy of Sciences and several professional societies from which he received professional awards for outstanding research. These include the Amgen Outstanding Investigator Award (ASIP, 2004), the Henry Pickering Bowditch Award (APS, 2006), the BD Biosciences Investigator Award (AAI,2007) and the Eugene Landis Award (MCS, 2010).

Scroll to Top

Contact Us

TL1A and IL-23

Morphic is leveraging its structural biology expertise and medicinal chemistry capabilities to develop small molecule therapeutic candidates against non-integrin targets including TL1-A and IL-23. Inhibition of these pathways have potential as treatments for IBD through monotherapy and possibly in combination with other IBD treatment mechanisms including α4β7 inhibition.

α5β1

Morphic is developing small molecule inhibitors of the integrin α5β1 based on research demonstrating that fibronectin integrin inhibition suppresses pulmonary arterial smooth muscle cell proliferation. Potential indications include severe pulmonary hypertensive disease including pulmonary arterial hypertension.

Integrin Partnership: Janssen

Morphic entered a research partnership with Janssen in 2019 to discover inhibitors of undisclosed integrin targets. In 2021, this partnership was expanded to include an antibody activator of an integrin target, extending the application of Morphic’s knowledge of integrin biology into modalities beyond small molecules. The antibody activator program is the focus of our collaboration with Janssen today.

Undisclosed Targets

Morphic is leveraging the MInT Platform to discover therapeutically relevant small molecule inhibitors of targets across the integrin family to treat autoimmune diseases, cancer and fibrotic diseases.

Undisclosed Target for Pulmonary Arterial Hypertension

Morphic is deploying the MInT Platform to create small molecule inhibitors of an undisclosed integrin target for evaluation as a potential treatment for pulmonary arterial hypertension (PAH). PAH is a devastating, usually fatal disease characterized by elevated mean pressures in the pulmonary artery and associated with lung and heart dysfunction. Morphic’s PAH program is in preclinical development.

αvβ8 (MORF-088)

Morphic is developing small molecule inhibitors of the integrin αvβ8 for potential uses in myelofibrosis and a combination immuno-oncology approach for the treatment of solid tumors. αvβ8 is known to activate selective isoforms of TGF-β and Morphic has demonstrated that αvβ8 inhibition can drive increased platelet production and potentiate immune checkpoint blockade and potentially drive responses in checkpoint refractory tumors. Morphic’s αvβ8 inhibitors are in preclinical development.

Next Gen α4β7 Inhibitors

Morphic is developing a family of next generation α4β7 small molecule inhibitors with enhanced attributes using the MInT Platform. These candidates have distinct chemical properties from our first-generation inhibitors with differentiated selectivity, potency, and pharmacokinetic profiles. Morphic’s next generation α4β7 inhibitors are currently in preclinical development.